Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

AIDS

Volumn 13, Issue 18, 1999, Pages

  Devereux, Helen L ^a,b   Youle, Mike ^b   Johnson, Margaret A ^b   Loveday, Clive ^a  

^a Department of Retrovirology ^*  (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

HIV protease; HIV reverse transcriptase; HIV 1 drug resistance; Rate of decline; Stopping antiretroviral therapy

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

EID: 0033385403     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912240-00001     Document Type: Article

References (17)

1. 1. Durant J, Clevenbergh P, Halfon P et al. Can HIV genotype determination be useful for individualised adaptation of antiretroviral therapy: The VIRADAPT French Study. Fourth International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract OP7.1].
2. 2. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC and the CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB8].
3. 3. Rodríguez-Rosado R, Briones C, Soriano V. Introduction of HIV drug-resistance testing in clinical practice. AIDS 1999, 13:1007-1014.
4. 4. Loveday C, Dunn D, McCormack, Babiker A. The use of HIV resistance assays - random or randomised? Sex Transm Inf 1999, 75:140-141.
5. 5. Hirsch MS, Conway B, D'Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998, 279:1984-1991.
6. 6. Boucher CA, van Leeuwen R, Kellam P et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency type 1 isolates. Antimicrob Agents Chemother 1993, 37:1525-1530.
7. 7. Batisse D, Karmochkine M, Si Mohamed A, Piketty C, Kazatchkine MD, Belec L. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy. AIDS 1998, 12:824-825.
8. 8. Smith MS, Koerber KL, Pagano JS. Long term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine treated patients removed from zidovudine therapy, J Infect Dis 1994, 169:184-188.
9. 9. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
10. 10. Back NK, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistanl HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme EMBO J 1996, 15:4040-4049.
11. 11. Youle M, Mocroft A, Johnson M et al. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 400],
12. 12. Kaye S, Loveday C, Tedder RS. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992, 37:241-246.
13. 13. Ruiz L, Nijhuis M, Boucher C et al. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:19-28.
14. 14. Larder BA, Kohli A, Kellam P et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.
15. 15. Coakley E, Gillis J, Hammer S. Mutations in the reverse transcriptase genome of HIV-1 isolates derived from subjects treated with didanosine and stavudine in combination. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 116].
16. 16. Calvez V, Mouroux M, Yvon A et al. Zidovudine resistance associated mutations can be selected in patients after long-term exposure to stavudine. Third International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, June 1999 [abstract 38].
17. 17. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials - compensatory modulations of binding and activity. J Biol Chem 1996, 271:31957-31963.